Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Canadian notice of deficiency for GlucaGen

May 31, 2006

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

May 30, 2006

Zetia approved for use in combination with fenofibrate

May 30, 2006

Phosphagenics reports positive preclinical results for transdermal insulin

May 30, 2006

Ceptyr selects IND-enabling studies for type 2 diabetes compound

May 30, 2006

Seasonique extended-cycle oral contraceptive receives FDA approval

May 29, 2006

Iplex now available for primary IGFD

May 29, 2006

Preclinical safety studies completed for oral calcitonin program

May 29, 2006

In vitro studies show osteoporosis treatment potential of kobophenol A

May 29, 2006

Cannabinoid receptor 2 a target for osteoporosis

May 29, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...